• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

50.96 -0.32 (-0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
These S&P500 stocks are moving in today's session ↗
January 22, 2026
Via Chartmill
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
January 22, 2026
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for... 
Via MarketMinute
Topics Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗
January 22, 2026
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday? ↗
January 22, 2026
Via Chartmill
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
January 21, 2026
Via Stocktwits
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
January 16, 2026
Via Stocktwits
Topics Intellectual Property
Top S&P500 movers in Thursday's session ↗
January 22, 2026
Via Chartmill
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
January 22, 2026
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Moderna Stock Explodes To New 52-Week High: What&#39;s Driving The Action? ↗
January 22, 2026
Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data. 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session ↗
January 22, 2026
Via Chartmill
News headline image
Why Moderna Stock Surged Today ↗
January 21, 2026
The vaccine maker is expanding beyond its COVID-focused offerings. 
Via The Motley Fool
These S&P500 stocks are moving in today's after hours session ↗
January 21, 2026
Via Chartmill
Discover which S&P500 stocks are making waves on Wednesday. ↗
January 21, 2026
Via Chartmill
News headline image
Moderna Stock Skyrockets To 52-Week High: What&#39;s Behind The Surge? ↗
January 21, 2026
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study. 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
January 21, 2026
Via Chartmill
News headline image
Moderna (MRNA) Shares Skyrocket, What You Need To Know
January 21, 2026
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year follow-up study of... 
Via StockStory
Topics Artificial Intelligence Government
News headline image
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
January 20, 2026
BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges. 
Via Stocktwits
News headline image
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? ↗
January 20, 2026
Via MarketBeat
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
January 20, 2026
Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
Via Stocktwits
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
January 20, 2026
Via ACCESS Newswire
News headline image
3 Healthcare Stocks Walking a Fine Line
January 18, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Stocks
Exploring the top movers within the S&P500 index during today's session. ↗
January 16, 2026
Via Chartmill
These S&P500 stocks are moving in today's session ↗
January 16, 2026
Via Chartmill
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
January 16, 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Top S&P500 movers in Friday's pre-market session ↗
January 16, 2026
Via Chartmill
Chips and Checks: AI and Banks Lead Wall Street's Charge ↗
January 16, 2026
Via Chartmill
Topics Artificial Intelligence
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
January 15, 2026
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
January 14, 2026
Via Chartmill
Topics Government
These S&P500 stocks are moving in today's session ↗
January 13, 2026
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap